| Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study JY Na, DY Yoon, H Yoo, SH Lee, KS Yu, IJ Jang, SK Yoo, Y Kim, J Oh Clinical and Translational Science 15 (11), 2744-2757, 2022 | 4 | 2022 |
| Influence of CYP2C19 polymorphisms on the pharmacokinetics of omeprazole in elderly subjects JY Na, I Jeon, J Yoon, Y Choi, SH Yoon, KS Yu, JY Chung Clinical Pharmacology in Drug Development 10 (12), 1469-1477, 2021 | 4 | 2021 |
| Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects JY Na, KY Huh, KS Yu, JY Hyon, HC Koo, JH Lee, JC You, JY Chung Clinical and Translational Science 15 (5), 1123-1130, 2022 | 3 | 2022 |
| Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment Y Park, JY Na, JY Cho, J Oh, S Rhee Frontiers in Pharmacology 13, 842836, 2022 | | 2022 |
| Comparative Pharmacokinetics Between a Fixed‐Dose Combination of Pitavastatin/Valsartan 4/160 mg and the Corresponding Individual Components Through a Partial Replicated … JY Na, E Yang, JH Kim, IS Kwon, EH Jin, KS Yu, J Kim, SH Lee, JH Hong Clinical Pharmacology in Drug Development 11 (5), 615-622, 2022 | | 2022 |
JAE-YONG CHUNGSeoul National University Bundang HospitalVerified email at snubh.org
